A 3-decade multicenter European experience with cladribine as upfront treatment in 384 hairy cell leukemia patients
Blood Advances(2022)
摘要
Cladribine is regarded as the first treatment of choice of symptomatic hairy cell leukemia (HCL): it provides high rates of response and very long duration of remission in some cases. Disease-specific patients records have been reviewed at four European centers of excellence; all patients with HCL requiring treatment who received frontline cladribine have been extrapolated. Responses have been classified according to Consensus Resolution Criteria. Three hundred and eighty-four patients have been diagnosed and followed between 1969 and 2018; all received frontline cladribine (subcutaneously or intravenously). A complete response was obtained in 72% of cases and a partial response in 22%. A continuous complete response was documented in 20% of patients at a median follow-up period of 8.5 years (range, 1-22 years). Median overall survival was reached at 25 years. Median progression-free survival was 13 years and median disease-free survival was 11 years. Cladribine is effective as frontline treatment of HCL and may determine deep disease control in a significant proportion of cases, given that more than 50% of treated patients require no further therapy. Good quality responses may be maintained for more than 20 years in up to 35% of patients.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要